These include, for instance, midostaurin for untreated FLT3-mutated AML currently undergoing a phase II trial [37], and inhibitors of mutated IDH1, such as ivosedinib that is Food and Drug Administration (FDA) approved for relapsed/refractory AML in children ≥12 years (NCT03245424). The gene discussed is FLT3; the disease is acute myeloid leukemia.